Company Information

  

Address: 373 INVERNESS PARKWAY
SUITE 206 
City: ENGLEWOOD 
State: CO 
Zip Code: 80112 
Telephone: (720) 437-6580 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a specialty pharmaceutical company focused on identifying, acquiring, and commercializing novel products that address significant patient needs. We have multiple FDA-approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales force and an international distribution network with presence in approximately fifty countries. We currently are focused on commercialization of four products, (i) Natesto®, a testosterone replacement therapy, or TRT, (ii) Tuzistra®XR, a codeine based antitussive, (iii) ZolpiMistTM, a short-term insomnia treatment and (iv), MiOXSYS®, a novel in vitro diagnostic system for male infertility assessment.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2019-1.84NAN/E
06/2019-3.48NAN/E
03/201925.37NA0.07
12/201846.57NA0.02
09/201817.88NA0.15
06/2018-306.20NAN/E
03/2018-3508.00NAN/E

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2019 Leverage 2019
Net Inc/Comm Equity-0.24Total Liab/Total Assets0.80
Net Inc/Total Assets-0.78Total Liab/Inv Cap0.94
Net Inc/Inv Cap-0.92Total Liab/Comm Equity0.24
Pretax Inc/Net Sales-3.71Interest Coverage RatioNA
Net Inc/Net Sales-3.71Curr Debt/EquityNA
Cash Flow/Net Sales-1.89LTD/Equity0.00
SG&A/NetSales2.63Total Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables Turnover6.31Quick Ratio2.60
Inventory Turnover1.58Current Ratio2.87
Inventory Day Sales0.00Net Rec/Curr Assets0.11
Net Sales/Work Cap0.73Inv/Curr Assets0.09
Net Sales/PP&E35.93  

Income Statement (Millions)

  9/30/2019 6/30/2019 3/31/2019 12/31/2018
Total Revenues(Net Sales) 1.44 1.72 2.38 1.80
Cost of Goods Sold 0.38 0.65 0.62 0.53
Selling & Admin Exps 5.15 4.90 5.38 5.14
Operating Income -4.74 -4.58 -4.30 -4.55
Interest Exp NA NA NA NA
Pretax Income -4.93 -14.53 -4.50 -4.66
Other Income -0.19 -9.95 -0.20 -0.11
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -4.93 -14.53 -4.50 -4.66

Balance Sheet (Millions)

Assets 9/30/2019 6/30/2019 3/31/2019 12/31/2018
Cash & Short Term Investments 7.26 11.29 14.75 17.91
Receivables - Total 2.71 1.74 1.38 1.48
Inventories - Total 1.38 1.44 1.53 1.64
Total Current Assets 11.98 15.43 18.46 21.98
Net Property, Plant & Equipment 0.53 0.20 0.22 0.19
Total Assets 31.02 34.72 38.34 42.40
Liabilities        
Accounts Payable 4.79 4.29 3.69 4.05
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 6.10 5.37 4.50 4.66
Long-Term Debt 0.01 0.01 5.16 5.06
Total Liabilities 28.70 27.63 22.30 22.50
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -111.32 -106.39 -91.86 -87.36
Treasury Stock NA NA NA NA
Total Stockholders' Equity 2.32 7.09 16.04 19.90
Total Liabilities and Stockholders' Equity 31.02 34.72 38.34 42.40

Cash Flow Summary (Millions)

Categories 9/30/2019 6/30/2019 3/31/2019 12/31/2018
Net Cash Provided by Operating Activities -2.99 -3.47 -3.31 -4.30
Net Cash Provided by Investing Activities -1.04 -0.10 -0.11 -0.56
Net Cash Provided by Financing Activities 0.00 0.12 0.26 18.70

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/20150.26-7.72--
06/20162.56-28.18--
06/20173.22-22.51--
06/20183.66-10.19-306.20
06/20197.32-27.13-3.48
Growth Rates129.96----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional12/31/19315,75527.76




Report Date : 1/20/2020

Powered By Edgar Online © 2020EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.